Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 21 to 30 of 121 total matches.
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
. Females of reproductive potential and
their male partners should use effective contraception
during ...
The FDA has approved the oral kinase inhibitor
quizartinib (Vanflyta – Daiichi Sankyo) for use
in combination with standard cytarabine and
anthracycline induction and cytarabine consolidation,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication (ITD)-positive, newly-diagnosed
acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70 doi:10.58347/tml.2023.1687d | Show Introduction Hide Introduction
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
contraception for
6 months after treatment.
The wholesale acquisition cost of one dose of
Roctavian for a 70 ...
Valoctocogene roxaparvovec-rvox (Roctavian –
Biomarin), an adeno-associated virus (AAV) vector-based
gene therapy, has been approved by the FDA
for one-time treatment of severe hemophilia A
in adults without pre-existing antibodies to AAV
serotype 5. It is the first gene therapy to be approved
in the US for treatment of hemophilia A.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):157-8 doi:10.58347/tml.2023.1686c | Show Introduction Hide Introduction
Opill — An OTC Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
Opill — An OTC Oral Contraceptive ...
The FDA has approved Opill (Perrigo), a progestin-only
oral contraceptive that contains norgestrel, for
sale over the counter (OTC). Opill is the first oral
contraceptive to be approved in the US for sale without
a prescription. Approval of OTC Opill is intended
to increase access to effective contraception and
reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2 doi:10.58347/tml.2023.1685c | Show Introduction Hide Introduction
Elranatamab (Elrexfio) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
effective
contraception during treatment with elranatamab
and for 4 months after the last dose ...
Elranatamab-bcmm (Elrexfio – Pfizer), a bispecific
B-cell maturation antigen (BCMA)-directed CD3
T-cell engager, has been granted accelerated
approval by the FDA for treatment of relapsed or
refractory multiple myeloma in adults who received
≥4 prior lines of therapy, including a proteasome
inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval
was based on the response rate and durability of
response. Elranatamab is the second bispecific
BCMA-directed CD3 T-cell engager to be approved for
this indication; teclistamab (Tecvayli) was the...
Med Lett Drugs Ther. 2023 Sep 18;65(1685):e153-4 doi:10.58347/tml.2023.1685d | Show Introduction Hide Introduction
Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
potential should
use effective contraception during treatment with
niraparib/abiraterone acetate and for 4 ...
Akeega (Janssen), a fixed-dose combination of
the oral poly(ADP-ribose) polymerase (PARP)
inhibitor niraparib (Zejula) and the antiandrogen
abiraterone acetate (Zytiga, and others), has been
approved by the FDA for use in combination with
prednisone for treatment of adults with deleterious
or suspected deleterious BRCA-mutated (BRCAm)
metastatic castration-resistant prostate cancer
(mCRPC). Niraparib has been available since 2017
for treatment of epithelial ovarian, fallopian tube, or
primary peritoneal cancer. Abiraterone acetate has
been available since 2011 for treatment of CRPC...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e146-7 doi:10.58347/tml.2023.1684c | Show Introduction Hide Introduction
Talquetamab (Talvey) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
or while breastfeeding. Females
of childbearing potential should use effective
contraception during ...
Talquetamab-tgvs (Talvey – Janssen), a bispecific
GPRC5D-directed T-cell engager, has been granted
accelerated approval by the FDA for treatment of
relapsed or refractory multiple myeloma in adults
who received ≥4 prior lines of therapy, including a
proteasome inhibitor, an immunomodulatory drug,
and an anti-CD38 monoclonal antibody. Accelerated
approval was based on the response rate and
durability of response. Talquetamab is the first
bispecific GPRC5D-directed T-cell engager to be
approved in the US
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e149-50 doi:10.58347/tml.2023.1684e | Show Introduction Hide Introduction
Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
should use effective
contraception during treatment with glofitamab and
for 1 month after the last dose ...
Glofitamab-gxbm (Columvi – Genentech), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for IV treatment of
relapsed or refractory diffuse large B-cell lymphoma
(DLBCL), not otherwise specified, or large B-cell
lymphoma (LBCL) arising from follicular lymphoma
after ≥2 lines of systemic therapy. Accelerated
approval was based on response rates and durability
of response. Glofitamab is the second T-cell-engaging
bispecific antibody to be approved in the US
for treatment of DLBCL; epcoritamab-bysp (Epkinly),
which is given...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e129-30 doi:10.58347/tml.2023.1682b | Show Introduction Hide Introduction
Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
use effective
contraception during treatment and for 6 weeks
after the last dose and males ...
The FDA has approved osimertinib (Tagrisso –
AstraZeneca), an oral kinase inhibitor, for adjuvant
treatment of non-small cell lung cancer (NSCLC)
after tumor resection in adults who have epidermal
growth factor receptor (EGFR) exon 19 deletions or
exon 21 L858R mutations. Osimertinib is the first
targeted therapy to be approved in the US for this
indication. The drug was previously approved for
first-line treatment of adults with NSCLC with EGFR
exon 19 deletions or exon 21 L858R mutations and for
treatment of EGFR T790M mutation-positive NSCLC
in adults whose disease progressed...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e131-2 doi:10.58347/tml.2023.1682c | Show Introduction Hide Introduction
Talazoparib (Talzenna) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
potential should use effective contraception during
treatment with talazoparib and for 4 months after ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor talazoparib (Talzenna – Pfizer) has been
approved by the FDA for use in combination with the
androgen receptor blocker enzalutamide (Xtandi) for
treatment of adults with homologous recombination
repair (HRR) gene-mutated metastatic castration-resistant
prostate cancer (mCRPC). The drug has
been available since 2018 for treatment of deleterious
or suspected deleterious germline BRCA-mutated
(gBRCAm), HER2-negative locally advanced or
metastatic breast cancer.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e134-5 doi:10.58347/tml.2023.1682e | Show Introduction Hide Introduction
Table: Safety of Drugs for IBD in Pregnancy (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
in pregnant women; teratogenic effects and fetal deaths in animal studies
Effective contraception should ...
View the Table: Safety of Drugs for IBD in Pregnancy
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e113 doi:10.58347/tml.2023.1680b | Show Introduction Hide Introduction